Racial differences in acute toxicities of neoadjuvant or adjuvant chemotherapy in patients with early-stage breast cancer
- 11 July 2011
- journal article
- research article
- Published by Elsevier BV in European Journal Of Cancer
- Vol. 47 (17), 2537-2545
- https://doi.org/10.1016/j.ejca.2011.06.027
Abstract
No abstract availableThis publication has 20 references indexed in Scilit:
- African‐American race is associated with a poorer overall survival rate for breast cancer patients treated with mastectomy and doxorubicin‐based chemotherapyCancer, 2006
- Comorbidity and Survival Disparities Among Black and White Patients With Breast CancerPublished by American Medical Association (AMA) ,2005
- Dose density in adjuvant chemotherapy for breast cancer.Cancer Investigation, 2004
- Differences in Breast Cancer Stage, Treatment, and Survival by Race and EthnicityArchives of Internal Medicine, 2003
- Acute toxicity of adjuvant doxorubicin and cyclophosphamide for early breast cancer – a retrospective review of Chinese patients and comparison with an historic Western seriesRadiotherapy and Oncology, 2002
- Dose and Dose Intensity as Determinants of Outcome in the Adjuvant Treatment of Breast CancerJNCI Journal of the National Cancer Institute, 1998
- Ethnic differences and factors related to breast cancer survival in HawaiiInternational Journal of Epidemiology, 1997
- Ethnicity and conditional breast cancer survival in HawaiiJournal of Clinical Epidemiology, 1997
- Adjuvant Cyclophosphamide, Methotrexate, and Fluorouracil in Node-Positive Breast Cancer — The Results of 20 Years of Follow-upNew England Journal of Medicine, 1995
- Dose and Dose Intensity of Adjuvant Chemotherapy for Stage II, Node-Positive Breast CarcinomaNew England Journal of Medicine, 1994